M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Roche launched its uPath software for digital pathology, billing it as an improvement in speed and performance over its previous version.
Brainsway, developer of transcranial magnetic device treatments for depression and OCD, plans to raise $30 million through a Nasdaq IPO.
The FDA plans to hire at least 50 reviewers for cell and gene therapies ahead of what it describes as a surge of products entering development.
Abbott received FDA approval for its Amplatzer Piccolo Occluder, which it describes as the world’s first implant for babies as little as two pounds.
CellMax Life was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy using a blood-based test.
The FDA cleared Ossio’s family of bio-integrative bone pins, which secure broken bones while leaving no permanent hardware behind.
GE Healthcare and Vanderbilt University are developing diagnostics that use AI to predict both efficacy and side effects of cancer immunotherapies.
PQ Bypass gathered $60 million in financing to move its minimally invasive tech for circumventing long blockages in leg arteries caused by PAD.
What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
At JPM, Propeller Health closed its $225 million buyout with ResMed and launched a partnership with Walgreens for in-app prescription refills.